All GLG News Analyses Filed Under: Cardiology

It is unclear to the generalist whether this is another antiplatlet drug or a thrombin inhibitor. In either case, bleeding vs imrovement will be the issue. The positive effects will need to out way any bleeding issues. 

This is a start on the long road to legitimizing stem cell therapeutics...in this case using adult stem cells. 

The only available oral inhibitor of thrombin is warfarin which is a nightmare compound to deal with from a level and DDI standpoint.   

The collaboration between Pfizer and BMS may help complete the  pivotal Phase III trials of apixapan quicklyA serious competitor to Abaxipan is Daigratan  ( Rendix, Boerhinger) an oral direct Thrombin inhibitor which is also already in pivotal Phase III trials for same indications

We have seen a shift come full circle.When I initially trained combo antihypertensives were in. Then single agent -add on therapy came into fashion. Now we are back to combo products. This clearly makes sense in light of the increase in obesity and hypertension-its difficulty to control and lowering...

Though I was not able to access this article, the recent Japanese study of 18,000 men demonstrated that the addition of the Omega-3 EPA alone (1800 mg per day) to statins had a favorable, statistically significant outcome in decreasing major coronary events than with statins alone.The Omega-3 fatty...

As we know the Paclitaxel is a taxoid drugs working against cancer by interfering with mitosis, decrease withe blood cell asnd plataletes , but today the thrombogeneity and pro- endothelialization effect are still important.My opinion convetional stent with statins anti-immflamtory...

It is unusual for a combination tablet (of the angiotensin receptor blocker irbesartan with the thiazide diuretic hydroclorothiazide) to be recommended as a first line agent. Combination tablets were often reserved for patients who had been titrated to appropriate effective doses and...

Heart transplant donor organs will now be available from anywhere in the world.Even if the same number of organs were available,  the ability to move these organs over greater distances without loss of viability will allow better matching and perhaps better long term outcomesLong term safety...

  The industry has virtually no choices but to do as the FDA says or go through a lengthy petition process when negative comments are stated from the FDA. However, in this case the FDA is warmly welcoming commenting on the drug.